| SOXS 1.79 4.07% | NVDA 177.19 -4.16% | ONMD 1.02 44.60% | NFLX 96.24 13.77% | JEM 0.096 3.90% | ENSC 0.6232 57.77% | BYND 0.9456 15.32% | PLUG 1.79 -6.28% | SOFI 17.76 -7.02% | NVD 7.53 8.50% | TZA 6.23 5.06% | NU 14.98 -0.53% | DUST 3.54 -3.50% | BITO 9.06 -2.78% | EOSE 5.695 -15.50% | XLF 51.43 -2.04% | BAC 49.83 -4.72% | AAL 13.07 -6.24% | MARA 8.94 5.80% | VEEA 0.5071 17.33% | SPY 685.99 -0.48% | SOXL 62.77 -3.93% | SLV 84.99 5.64% | XWEL 1.49 9.56% | QQQ 607.29 -0.32% | ONDS 10.08 -3.54% | BHAT 0.0495 -11.13% | PSKY 13.51 20.84% | INTC 45.61 0.33% | F 14.095 -2.19% | AAPL 264.18 -3.21% | XLE 55.92 1.58% | TQQQ 49.52 -1.06% | TSLA 402.51 -1.49% | HYG 80.72 -0.16% | TSDD 9.18 2.91% | TSLL 14.7 -3.10% | BATL 5.52 33.01% | RKT 18.19 2.36% | RXT 1.95 -14.47% | TLT 90.82 0.61% | TSLS 5.64 1.62% | WBD 28.17 -2.19% | PATH 10.73 0.14% | CRWV 79.56 -18.51% | IBIT 37.19 -2.80% | LQD 111.68 -0.04% | SOUN 8.6015 -4.21% | PLTR 137.19 0.92% | CPNG 19.08 1.98%

LifeVantage Corporation (NASDAQ: LFVN) Q4 Earnings Overview

LifeVantage Corporation (NASDAQ: LFVN) is a health and wellness company known for its focus on nutritional supplements and skincare products. The company operates globally, with significant markets in the Americas, Asia/Pacific, and Europe. LifeVantage competes with other health and wellness companies, striving to maintain its market position through innovative products and strategic growth.

On September 4, 2025, LifeVantage reported its Q4 earnings, revealing an earnings per share (EPS) of $0.14, which fell short of the expected $0.17. Despite this, the company showed a year-over-year improvement, with net income per diluted share rising to $0.15 from $0.10. Adjusted earnings per diluted share also increased to $0.17 from $0.14, indicating some positive financial momentum.

The company's revenue for the fourth quarter was $55.1 million, below the anticipated $57.9 million. However, this still represented a 12.6% increase from the previous year. In the Americas, revenue grew by 14.1%, while Asia/Pacific and Europe saw a 7.6% increase. Excluding foreign currency impacts, the growth in Asia/Pacific and Europe was 1.6%, highlighting regional performance variations.

LifeVantage's financial metrics provide further insight into its market position. The company has a price-to-earnings (P/E) ratio of 15.22 and a price-to-sales ratio of 0.67, indicating how the market values its earnings and revenue. The enterprise value to sales ratio is 0.62, suggesting a slightly lower valuation when accounting for debt and cash.

The company's financial health is supported by a debt-to-equity ratio of 0.36, reflecting moderate debt levels. With a current ratio of 1.66, LifeVantage demonstrates strong liquidity, ensuring it can meet short-term liabilities. The earnings yield of 6.57% offers insight into the earnings generated per dollar invested, showcasing the company's profitability.

Published on: September 5, 2025